Skip to content
Screener

Corvus Pharmaceuticals CRVS Total Liabilities

Total Liabilities at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$10.02B+21.0%
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
$55.11M-4.0%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$42.03M+49.1%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$187.06M-22.9%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$44M-12.0%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
$179.49M-14.1%

Other financials

Income statement

See full
Operating income-$14.9M-49.9%
Net income-$13.7M-190%
EPS (diluted)-$0.15-15.4%

Balance sheet

See full
Cash & equivalents$40.1M+702%
Total debt$834.0K-27.7%
Total equity$240.7M+388%
Total assets$253.2M+326%

Cash flow

See full
Operating cash flow-$10.4M-25.5%
CapEx$91.0K+153%
Free cash flow-$10.5M-26.1%

Valuation

See full
Market cap$1.16B+243%
Enterprise value$1.12B+245%

Returns & leverage

See full
Return on equity-30.5%-12.5pp
Debt / equity0.0×
Current ratio19.8×+14.9×

Where this comes from

Reported directly by Corvus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The source filing: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:05 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-057100
Line itemMarch 31, 2026December 31, 2025
Accrued and other liabilities6,9856,486
Total current liabilities12,1109,380
Operating lease liability406534
Total liabilities12,5169,914
Commitments and contingencies (Note 15)
Stockholders’ equity:
Preferred stock: $0.0001 par value; 10,000,000 shares authorized at March 31, 2026 and December 31, 2025; 0 shares issued and outstanding at each of March 31, 2026 and December 31, 2025
Common stock: $0.0001 par value; 290,000,000 shares authorized at March 31, 2026 and December 31, 2025; 84,090,424 and 74,696,629 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively87

Item 1. Financial Statements (unaudited)

FAQ

What is Corvus Pharmaceuticals's total liabilities?
Corvus Pharmaceuticals (CRVS) reported total liabilities of $12.52M in Q1 2026.
How has Corvus Pharmaceuticals's total liabilities changed year-over-year?
Corvus Pharmaceuticals's total liabilities increased by 23.8% year-over-year, from $10.11M to $12.52M.
What is the long-term trend for Corvus Pharmaceuticals's total liabilities?
Over 5 years (2020 to 2025), Corvus Pharmaceuticals's total liabilities has grown at a -5.8% compound annual growth rate (CAGR), from $13.38M to $9.91M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.

Ask your AI about Corvus Pharmaceuticals's total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude